SMMT Stock Summit Therapeutics Inc.

$9.95
1d-5.87%5d-29.68%1m-37.14%ytd-43.11%
At close · Nov 20, 4:00 PM ET
After hours $10.08 +1.31% · Nov 20, 7:42 PM ET
52w low $9.890% of range$29.23 52w high
Price

Today’s call · SMMT

All live ideas →

6 of 6 technical checks lean bearish

SMMT is in a downtrend, momentum soft. $10 is the level overhead; $9 the first support below.

No open idea.Levels allow 19:1, but there is no confirmed entry yet — no breakout or pullback signal.
What would create one:
  • A close below $9 on rising volume (breakdown).
  • A bounce to $10 that fails (entry near resistance).
Alert me at a level

The brief

Price vs 50-day · belowPrice vs 200-day · below50d vs 200d avg · belowMACD · bearishRSI momentum · 305-day tape · -29.7%
signalSMMT’s 50-day average is below the 200-day — long-term trend alignment is bearish.
levelPrice is 0.5% from resistance $10.0 — watch for a break or rejection.
volumeVolume is expanding vs its 20-day average.
newsSummit Therapeutics Inc. — Form 8-K: 8.01 Other Events; 9.01 Financial Statements and Exhibits
All readings
TrendDowntrend · below 50-day & below 200-day
MomentumRSI 30.3 · MACD bearish
Trend strengthADX 25.5 · strong trend
Location-36.8% vs 50-day MA
52-week range-62% from high · +0% from low
VolatilityATR 1.48 · ~14.9%/day
RSI 14
30.3
MACD
-1.37
ADX 14
25.5
ATR 14
1.48
SMA 50
$15.74
SMA 200
$16.06

Levels that matter

$10round+0.5%
$11round+10.6%
$14.58swing zone · 2×+46.5%
$9round−9.6%
$8round−19.6%

Compare with…

Analyst overview · Nov 15 · updated Nov 18

Summit Therapeutics (SMMT) bears down on $14 price

Update, November 18, 2026

Since the November 15 report, SMMT has fallen to $10.67, a 9.73% drop on the day and a cumulative 40.16% decline over five days, outpacing the S&P 500’s 2.33% dip and lagging the healthcare sector XLV’s 1.93% slide, reinforcing the bearish picture.

The picture holds: the stock remains below the 10.0 round support and still sits under the 11.0 resistance level where sellers have historically emerged. The daily close stays above the breakout threshold of 10.0, so the downside breakout condition has not been met, and the stop at 11.38 remains intact. The weekly close has not breached the 15.17 swing‑zone resistance, so the condition that would change the picture – a weekly close above 15.17 – remains unmet.

Volume is 115.1% of its 20‑day average, indicating heightened activity, while the 50‑day SMA sits at $16.16 and the 200‑day SMA at $16.12, both well above the current price. RSI is at 31.98, suggesting continued weakness. The recent FDA Complete Response Letter, reported by SEC EDGAR, adds product‑specific pressure. With the stock at the low end of its 52‑week range and no change in the key levels, the bearish stance remains unchanged.

Summit Therapeutics (SMMT) closed at $14.15 on November 13, a steep 13.3% drop over the past five days that left the stock well below its 40‑week average. The daily trend follows a weekly downtrend, and the balance of evidence points to a bearish outlook for the next two to six weeks. With a high conviction based on three of four key points, the math shows a downside breakout target near $12.43 and a stop around $14.92, but the risk‑reward ratio falls short of the 3‑to‑1 threshold.

Why it matters

The recent plunge was not driven by any specific news; the market simply re‑priced the stock after a sharp one‑day fall of more than 5%, a move that historically precedes a further 61.8% decline over the following month. The sector, represented by the XLV health‑care ETF, rose 2.2% in the same five‑day window, while the S&P 500 gained 2.6%. The stock’s underperformance versus both the market (‑15.5%) and the sector (‑20.4%) underscores a relative weakness that is not explained by broader market strength.

From a valuation perspective, analysts’ consensus remains a “buy” with a mean target of $29.52, yet the current price sits 52.1% below that level. The spread between the low target ($11.72) and the high target ($42.19) is wide, reflecting divergent expectations, but the median target still lies far above today’s price, indicating that the consensus may be overly optimistic given the price action.

The debate among market participants centers on whether the recent sell‑off is a temporary overreaction or a sign of deeper structural weakness. Proponents of a rebound point to the consensus “buy” rating and the long‑term upside potential implied by the high target range. Critics highlight the stock’s failure to hold above the $14.58 swing zone, its position below both the 50‑day ($16.41) and 200‑day ($16.15) simple moving averages, and a relative strength index of 42, suggesting limited buying momentum.

Both sides agree that the weekly trend is down and that the price is now trading below the 40‑week average, a classic bearish signal. The evidence therefore leans toward a continuation of the decline rather than a swift reversal.

What the evidence says

On the long‑term horizon the thesis that SMMT is in a downtrend remains intact. The price is well under the 40‑week average, the 52‑week range shows a 46.4% drop from the high of $26.38, and the stock sits 13.8% above its 52‑week low of $12.43. The weekly trend aligns with the daily move, reinforcing the bearish bias.

Looking ahead to the next two‑to‑six weeks, the balance of evidence is negative with a high conviction. Three of four conviction points support the bearish stance: the daily trend mirrors the weekly downtrend, the stock lags the S&P 500 by 12.6% over 50 days, and it lags the health‑care sector XLV by 20.4% over the same period. The strongest counter‑argument is the consensus “buy” rating and the mean target near $30, but the price’s current distance from that target (‑52%) and the lack of any catalyst make that case insufficient to overturn the bearish reading.

Levels that matter

The structure holds the price above the $14.58 swing zone, a level where sellers have repeatedly stepped in on rally attempts. A close above $15.17 would signal the end of the current downtrend, as that level marks the top of the swing‑zone range that has previously acted as resistance.

The downside breakout math is triggered by a daily close below the round $14.0 level. The stop is set at $14.92, derived from the $14.58 swing zone plus a quarter of the 14‑day ATR ($1.34). The primary target is $12.43, the 52‑week low, offering a reward‑to‑risk of roughly 1.7. Because the math does not achieve a 3‑to‑1 ratio, a price move to about $11.30 would be needed to meet that threshold.

What would change the picture

A weekly close above $15.17 would alter the narrative, indicating that the downtrend has been broken. The single non‑price factor that could also shift the outlook is the upcoming earnings release on November 5; a surprise positive earnings surprise could provide the catalyst needed to lift the stock above the swing‑zone resistance.

What to watch

  • November 5 earnings – focus on the earnings per share number and any forward guidance.
  • Sector developments – any FDA approvals or setbacks affecting biotechnology peers could move SMMT before its own news.
  • Valuation – the stock remains more than 50% below the mean analyst target, a gap that will be scrutinized against any earnings surprise.

MarketCrew is AI-powered and can make mistakes — double-check before acting. Informational only, not investment advice.